Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersPresented updated preclinical activity of BDC-4182 and key learnings...
BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from...
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
REDWOOD CITY, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersAbstract accepted for BDC-4182, a claudin 18.2-targeting BoltbodyTM ISAC at the...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0791 | 14.1224781289 | 0.5601 | 0.65 | 0.56 | 178684 | 0.61000662 | CS |
| 4 | -0.0098 | -1.51001540832 | 0.649 | 0.69 | 0.54 | 116616 | 0.60176657 | CS |
| 12 | -0.0109 | -1.67666512844 | 0.6501 | 0.718 | 0.54 | 141239 | 0.62494157 | CS |
| 26 | -0.1208 | -15.8947368421 | 0.76 | 0.795001 | 0.54 | 151526 | 0.68392922 | CS |
| 52 | -0.2708 | -29.7582417582 | 0.91 | 1.56 | 0.54 | 164916 | 0.87298982 | CS |
| 156 | -8.4608 | -92.9758241758 | 9.1 | 10.705 | 0.54 | 200565 | 1.92632833 | CS |
| 260 | -21.3508 | -97.0932241928 | 21.99 | 43.07 | 0.54 | 190110 | 6.64555631 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
